KYMR
KYMR
NASDAQ · Biotechnology

Kymera Therapeutics Inc

$74.42
-2.54 (-3.30%)
As of Mar 24, 9:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
50.82M
Net Income
-241,650,965
Gross Margin
Profit Margin
-475.6%
Rev Growth
-13.5%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 63.8% 63.8%
Operating Margin -555.8% -500.2% 5.7% 5.2%
Profit Margin -475.6% -451.8% 4.3% 4.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 50.82M 58.78M 7.83B 9.20B
Gross Profit 5.00B 5.87B
Operating Income -282,452,049 -294,016,706 447.05M 479.50M
Net Income -241,650,965 -251,545,071 335.40M 415.81M
Gross Margin 63.8% 63.8%
Operating Margin -555.8% -500.2% 5.7% 5.2%
Profit Margin -475.6% -451.8% 4.3% 4.5%
Rev Growth -13.5% -13.5% +18.7% +14.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 15.30M 15.30M 1.80B 1.98B
Total Equity 3.40B 3.40B 3.36B 3.32B
D/E Ratio 0.00 0.00 0.53 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -274,475,963 -301,587,051 592.59M 664.46M
Free Cash Flow 369.62M 455.69M